These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1897286)

  • 1. [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
    Schaberg T; Lode H
    Z Gesamte Inn Med; 1991 Jun; 46(8):276-9. PubMed ID: 1897286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
    Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tisamide in the complex treatment of tuberculosis].
    Onishchenko VV; Sokolova GB; Koriakin VA; Shapatava MN; Iurchenko LN
    Probl Tuberk; 1990; (7):43-5. PubMed ID: 2235951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Nowak D; Radenbach D; Magnussen H
    Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and experimental data in support of the use of a fixed-triple combination of isoniazid, rifampicin and pyrazinamide in the chemotherapy of tuberculosis.
    Acocella G
    G Ital Chemioter; 1987; 34(1-3):3-5. PubMed ID: 3504412
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 13. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
    Musch E; Loos U; Schwabe HK
    Pneumologie; 1990 Feb; 44 Suppl 1():486-7. PubMed ID: 2367444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
    De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.